Preferred Label : ravulizumab;
MeSH hyponym : ALXN1810; ALXN-1210;
UNII : C3VX249T6L;
Origin ID : C000629409;
UMLS CUI : C4550350;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3527465/fr/ultomiris-ravulizumab-inhibiteur-du-complement-c5
2024
false
false
false
France
insurance, health, reimbursement
infusions, intravenous
ravulizumab
evaluation of the transparency committee
complement inactivating agents
complement inactivator proteins
complement C5
ravulizumab
---
https://ansm.sante.fr/tableau-marr/ravulizumab
2024
false
false
false
France
French
risk management
ravulizumab
ravulizumab
ravulizumab
infusions, intravenous
guidelines for drug use
patients guideline
continuity of patient care
meningococcal infections
sepsis
neisseria meningitidis
vaccination
antibiotic prophylaxis
meningococcal infections
sepsis
child
infant
hemoglobinuria, paroxysmal
Atypical Hemolytic Uremic Syndrome
myasthenia gravis, generalized
---
https://ansm.sante.fr/tableau-acces-derogatoire/ultomiris
2024
false
false
false
France
French
infusions, intravenous
ravulizumab
ravulizumab
generalised myasthenia gravis with anti-acetylcholine receptor antibody
myasthenia gravis, generalized
adult
Adult-onset myasthenia gravis
drug information
---
https://www.has-sante.fr/jcms/p_3419442/fr/ultomiris-ravulizumab-myasthenie-acquise-generalisee-mag
2023
false
false
false
France
ravulizumab
treatment outcome
insurance, health, reimbursement
Anti-acetylcholine receptor antibody positivity
Acetylcholine receptor antibody (substance)
drug therapy, combination
adult
infusions, intravenous
evaluation of the transparency committee
myasthenia gravis
ravulizumab
myasthenia gravis, generalized
---
https://www.has-sante.fr/jcms/p_3455563/fr/ultomiris-ravulizumab-myasthenie-acquise-generalisee
2023
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
ravulizumab
ravulizumab
myasthenia gravis, generalized
adult
---
https://www.has-sante.fr/jcms/p_3433398/fr/ultomiris-ravulizumab-syndrome-hemolytique-et-uremique-atypique-shua
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
ravulizumab
complement C5
complement inactivating agents
evaluation of the transparency committee
ravulizumab
Atypical Hemolytic Uremic Syndrome
---
https://www.has-sante.fr/jcms/p_3456902/fr/ultomiris-ravulizumab-neuromyelite-optique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
ravulizumab
Product containing only ravulizumab in parenteral dose form (medicinal product form)
infusions, intravenous
adult
neuromyelitis optica spectrum disorders who are anti-aquaporin 4 antibody positive
Neuromyelitis optica spectrum disorder with anti-AQP4 antibodies
evaluation of the transparency committee
neuromyelitis optica
ravulizumab
---
https://www.has-sante.fr/jcms/p_3341428/fr/ultomiris-ravulizumab-myasthenie-acquise-generalisee
https://has-sante.fr/jcms/p_3341529/fr/decision-n-2022-0165/dc/sem-du-19-mai-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-ultomiris
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
adult
Adult-onset myasthenia gravis
ravulizumab
infusions, intravenous
evaluation of the transparency committee
ravulizumab
myasthenia gravis
myasthenia gravis, generalized
---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1175
2022
France
public health guidelines
eculizumab
judgment
complement inhibitor, nos
complement inactivating agents
ravulizumab
patients
eculizumab
bacterial infectious disease, nos
Complement
eculizumab
Infectious disease
has patient
bacterial infections
ravulizumab
prophylactic treatment, nos
---
https://www.has-sante.fr/jcms/p_3358127/fr/ultomiris-ravulizumab-hemoglobinurie-paroxystique-nocturne-chez-les-patients-pediatriques
2022
false
false
false
France
ravulizumab
insurance, health, reimbursement
treatment outcome
infusions, intravenous
child
evaluation of the transparency committee
hemoglobinuria, paroxysmal
ravulizumab
paroxysmal nocturnal hemoglobinuria
---
https://www.has-sante.fr/jcms/p_3274202/fr/ultomiris-ravulizumab-shua
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Product containing only ravulizumab in parenteral dose form (medicinal product form)
Atypical Hemolytic Uremic Syndrome
complement inactivating agents
ravulizumab
adult
child
evaluation of the transparency committee
ravulizumab
Ultomiris
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3281239/fr/ultomiris-300-mg/3-ml-ravulizumab
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
Ultomiris
ravulizumab
infusions, intravenous
complement inactivating agents
ravulizumab
paroxysmal nocturnal hemoglobinuria
adult
Atypical Hemolytic Uremic Syndrome
---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=959
2020
false
false
false
France
Invasive meningococcal disease (disorder)
antibiotic prophylaxis
vaccination
meningococcal vaccines
pneumococcal vaccines
haemophilus vaccines
haemophilus infections
pneumococcal infections
immunocompromised host
immunization schedule
adult
child
penicillin V
public health guidelines
eculizumab
meningococcal infections
ravulizumab
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3202251/fr/ultomiris
2020
false
false
false
France
infusions, intravenous
Product containing only ravulizumab in parenteral dose form (medicinal product form)
ravulizumab
insurance, health, reimbursement
ravulizumab
complement inactivating agents
treatment outcome
adult
paroxysmal nocturnal hemoglobinuria
evaluation of the transparency committee
hemoglobinuria, paroxysmal
antibodies, monoclonal, humanized
---
https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ravulizumab
ravulizumab
adult
paroxysmal nocturnal hemoglobinuria
infusions, intravenous
complement inactivating agents
complement inactivating agents
complement C5
product surveillance, postmarketing
chronic disease
aged
pregnancy
breast feeding
drug evaluation, preclinical
ravulizumab
Atypical Hemolytic Uremic Syndrome
hemoglobinuria, paroxysmal
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
---
